Introduction
Invitrocue’s Patient-derived tumor organoids (PDOs) are multicellular in vitro tissue construct derived from patients diagnosed with metastatic cancer. PDOs recapitulates the genetic, morphological features and heterogeneity of the native tumor. At Invitrocue, we regenerate the 3D tumour microenvironment using our propriety 3D cell culture technology. This provides a more clinically relevant model for preclinical drug efficacy and toxicity assessment.
Features / strengths
•High-Throughput: PDOs are scalable to minimize the donor-to-donor variation
•Heterogeneity: Evaluation of drug efficacy and toxicity in different patient
•Clinically Relevant: Data are more translational to clinical treatment outcome
•Personalization: Retain patient’s tumor complexity & drug resistance characteristics
Specification in detail
Certification
CE European Certification
Supporting document
